Phase 3, double-blind, multicenter study to evaluate the efficacy and safety of CAEL-101 and plasma cell dyscrasia treatment compared to placebo and plasma cell dyscrasia treatment in plasma cell dyscrasia treatment-naïve patients with stage AL amyloidosis IIIb Mayo.
Project objectivesThe primary objectives are:
|
Start and end date |
March 2022 |
Project Manager |
Ombretta Annibali - Principal Investigator |
Coordinating institution of the project |
IRCCS San Matteo polyclinic in Pavia |
Other Institutions involved |
|
Funding source(s). |
• Sponsored Alexion |